J&J Immunology Growth Now Hinges On Stelara, Tremfya After RA Setback
The company said it will pull global regulatory filings for the interleukin-6 inhibitor sirukumab for rheumatoid arthritis after determining regulatory delays would put it too far behind the competition.
You may also be interested in...
The company outlined pharma growth drivers, including 14 currently marketed medicines that will achieve $1bn or more in sales by 2020 and 10 new filings through 2023.
This year's ASH meeting reflected a peak of development success, with many new approvals and many more in the pipeline.
The pharmaceutical business continues to withstand the arrival of more Remicade biosimilars and the firm maintains it will have solid growth even with generic competition to its Zytiga.